Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Yamashita, Hiroharu ^a   Kitayama, Joji ^a   Kanno, Nobuko ^a   Yatomi, Yutaka ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSFIBRINOGENEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HEMOSTASIS; HUMAN; HYPERFIBRINOGENEMIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PREOPERATIVE EVALUATION; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH CANCER;

AGED; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FEMALE; FIBRINOGEN; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ODDS RATIO; PERITONEUM; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33745953732     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-147     Document Type: Article

References (33)

1. Trousseau A: Phlegmasia alba dolens. In Clinique Medicale de L'Hotel Dieu de Paris 2nd edition. Paris, Balliere; 1865:654-656.
2. Sun NC, McAfee WM, Hum GJ, Weiner JM: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979, 71(1):10-16.
3. Luzzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol 1990, 17(2):147-159.
4. Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA: Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999, 93(2):71-78.
5. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002, 9(3):287-291.
6. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004, 198(5):737-741.
7. Costantini V, Zacharski LR, Moritz TE, Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb Haemost 1990, 64(4):501-505.
8. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000, 86(3):203-207.
9. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000, 78(2):137-142.
10. Unsal E, Atalay F, Atikcan S, Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004, 98(2):93-98.
11. Buccheri G, Torchio P, Ferrigno D: Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003, 97(12):3044-3052.
12. Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001, 31(8):388-394.
13. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C: Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004, 101(1):77-82.
14. Dvorak HF: Thrombosis and cancer. Hum Pathol 1987, 18(3):275-284.
15. Lee JH, Ryu KW, Kim S, Bae JM: Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 2004, 51(60):1860-1863.
16. Yamashita H, Kitayama J, Nagawa H: Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005, 35(10):595-600.
17. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96(10):3302-3309.
18. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002, 62(23):6966-6972.
19. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005, 105(1):178-185.
20. Japanese Gastric Cancer A: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998, 1(1):10-24.
21. Ernst E, Koenig W: Fibrinogen and cardiovascular risk. Vasc Med 1997, 2(2):115-125.
22. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC: Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr 1998, 128(8):1355-1360.
23. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM: Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001, 84(12):1602-1609.
24. Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y: Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992, 1(5):341-346.
25. Otsuji E, Kuriu Y, Ichikawa D, Okamoto K, Ochiai T, Hagiwara A, Yamagishi H: Time to death and pattern of death in recurrence following curative resection of gastric carcinoma: analysis based on depth of invasion. World J Surg 2004, 28(9):866-869.
26. Yano H, J. K, Hatano K, Tsuno N, Osada T, Watanabe T, Tsuruo T, Muto T, Nagawa H: Clustered cancer cells show a distinct adhesion behavior from single cell form under physiological shear conditions. J Exp Clin Cancer Res 2001, 20(3):407-412.
27. Nieswandt B, Hafner M, Echtenacher B, Mannel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59(6):1295-1300.
28. Iversen LH, Thorlacius-Ussing O: Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002, 87(3):402-408.
29. Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, Ambrogi V, Spila A, D'Alessandro R, Gazzaniga PP, Guadagni F, Ferroni P: Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003, 89(1):177-184.
30. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, Nunziata L, Di Micco B, Torella R: Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001, 33(7):546-550.
31. Wojtukiewicz MZ, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Rozanska-Kudelska M, Kisiel W, Kudryk BJ: Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000, 97(5):335-342.
32. Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C: Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy. Scand J Gastroenterol 1994, 29(6):516-521.
33. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H: Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004, 103(5):1728-1734.